Business Wire |
Gene Therapy Looks Promising for Transfusion-Dependent β-Thalassemia
Monthly Prescribing Reference A majority of patients with transfusion-dependent β-thalassemia (TDT) were able to achieve freedom from chronic blood transfusion after receiving the gene therapy LentiGlobin (autologous CD34+ cells transduced with the BB305 vector; bluebird bio, Inc ... bluebird bio (BLUE) Highlights NEJM Publication of Interim Data ... |
from phlebotomy - Google News http://bit.ly/2Hduzk7
No comments:
Post a Comment